Drug Profile
IMCY 0098
Alternative Names: IMCY-0098Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator ImCyse
- Class Antihyperglycaemics; Peptides; Recombinant proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 1 diabetes mellitus
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in Denmark (SC, Injection)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in France (SC, Injection)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in Germany (SC, Injection)